Entrada Therapeutics, Inc. (NASDAQ:TRDA) COO Nathan J. Dowden Sells 1,904 Shares

Entrada Therapeutics, Inc. (NASDAQ:TRDA) COO Nathan J. Dowden sold 1,904 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $15.07, for a total value of $28,693.28. Following the completion of the sale, the chief operating officer now owns 125,996 shares of the company’s stock, valued at approximately $1,898,759.72. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Entrada Therapeutics Stock Performance

NASDAQ TRDA opened at $14.86 on Friday. The stock has a market cap of $552.79 million, a PE ratio of 23.59 and a beta of -0.24. Entrada Therapeutics, Inc. has a 12 month low of $10.75 and a 12 month high of $18.17. The stock’s 50 day moving average is $16.05 and its 200 day moving average is $14.66.

Entrada Therapeutics (NASDAQ:TRDA) last announced its quarterly earnings results on Tuesday, August 13th. The company reported $1.55 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.90. The firm had revenue of $94.69 million during the quarter, compared to the consensus estimate of $55.00 million. Entrada Therapeutics had a net margin of 43.63% and a return on equity of 35.16%. On average, analysts forecast that Entrada Therapeutics, Inc. will post 0.68 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on TRDA. Oppenheimer reiterated an “outperform” rating and issued a $25.00 price objective on shares of Entrada Therapeutics in a research report on Monday, August 26th. HC Wainwright restated a “buy” rating and set a $18.00 price target on shares of Entrada Therapeutics in a research note on Wednesday, August 14th.

Institutional Trading of Entrada Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of TRDA. Renaissance Technologies LLC purchased a new stake in Entrada Therapeutics in the 2nd quarter valued at about $636,000. American Century Companies Inc. increased its holdings in Entrada Therapeutics by 5.1% during the second quarter. American Century Companies Inc. now owns 384,973 shares of the company’s stock valued at $5,486,000 after buying an additional 18,625 shares during the period. Bank of New York Mellon Corp raised its position in shares of Entrada Therapeutics by 13.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 125,436 shares of the company’s stock worth $1,787,000 after acquiring an additional 14,838 shares in the last quarter. Marshall Wace LLP lifted its position in shares of Entrada Therapeutics by 27.5% during the second quarter. Marshall Wace LLP now owns 65,943 shares of the company’s stock valued at $940,000 after buying an additional 14,220 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in shares of Entrada Therapeutics by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 1,078,908 shares of the company’s stock worth $15,288,000 after buying an additional 13,742 shares during the last quarter. Hedge funds and other institutional investors own 86.39% of the company’s stock.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.